Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Shares Shorted: Short Interest Down 50.4% in September

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) saw a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 131,482 shares, a decline of 50.4% from the August 31st total of 265,115 shares. Currently, 3.1% of the shares of the company are short sold. Based on an average daily volume of 4,781,987 shares, the days-to-cover ratio is currently 0.0 days.

Insider Activity at Bluejay Diagnostics

In related news, major shareholder Financial Lp Hrt sold 34,938 shares of the business’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $1.40, for a total value of $48,913.20. Following the transaction, the insider owned 92,055 shares in the company, valued at $128,877. The trade was a 27.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 6.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on BJDX. Wall Street Zen downgraded Bluejay Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, September 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Monday, September 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Bluejay Diagnostics Stock Performance

Bluejay Diagnostics stock traded up $0.00 during midday trading on Tuesday, reaching $0.96. The company’s stock had a trading volume of 86,258 shares, compared to its average volume of 2,451,344. Bluejay Diagnostics has a fifty-two week low of $0.80 and a fifty-two week high of $16.68. The stock’s 50 day simple moving average is $0.96 and its 200 day simple moving average is $1.83. The firm has a market capitalization of $4.29 million, a PE ratio of -0.14 and a beta of 0.91.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($1.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3,520.00) by $3,518.88.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc is a medical technology company developing rapid, near-patient diagnostic solutions for use in hospitals and other care settings. The company’s focus is on helping clinicians obtain actionable information from small blood samples without relying exclusively on centralized laboratory testing.

Its primary product platform, the Symphony System, combines a reusable analyzer with disposable test cartridges designed to analyze whole-blood biomarkers. The platform’s initial focus has been the Symphony IL-6 Test, which measures interleukin-6, an inflammatory biomarker associated with immune-system activation and conditions such as sepsis.